FreeStyle Libre 3
Device
Abbott Laboratories
Total Payments
$1.0M
Transactions
106
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $314,046 | 55 | 1 |
| 2023 | $685,625 | 50 | 0 |
| 2021 | $37,472 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.0M | 106 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Dexcom G7 vs FreeStyle Libre 3 Continuous Glucose Monitoring System Accuracy Study | Abbott Laboratories | $495,148 | 0 |
| Glucose Metrics using Freestyle Libre 3 Real-Time Continuous Glucose Monitor (rtCGM) in Patients wit | Abbott Laboratories | $150,000 | 0 |
| CGM Comparison Study | Abbott Laboratories | $77,548 | 0 |
| Glucose Metrics using Freestyle Libre 3 Real-Time Continuous Glucose Monitor (rtCGM) in Patients with Gastroparesis in Type 1 or Type 2 Diabetes: Investigator Initiated Pilot Trial | Abbott Laboratories | $77,066 | 0 |
| Samita Garg, MD | Abbott Laboratories | $75,000 | 1 |
| FreeStyle Libre 3 Continuous Glucose Monitoring System Confirmation Study | Abbott Laboratories | $47,110 | 0 |
| Optimizing glycemic control using Freestyle Libre 2 (or newer version) after kidney transplantation | Abbott Laboratories | $46,569 | 0 |
| Multi-Analyte Studies | Abbott Laboratories | $13,067 | 0 |
| Prolongation of GLP-1 Adherence when using Continuous Glucose Monitoring | Abbott Laboratories | $10,606 | 0 |
| FreeStyle Libre 3 Continuous Glucose Monitoring System | Abbott Laboratories | $9,440 | 0 |
| Abbott Freestyle LIBrE 3 Continuous glucose MonitoRing QuAlity IniTiativE (LIBERATE) | Abbott Laboratories | $7,553 | 0 |
| Assessing the Glycemic Impact of an Online Lifestyle Intervention using CGM (Continuous Glucose Monitoring) | Abbott Laboratories | $5,444 | 0 |
| Prolongation of GLP-Adherence when using Continuous Glucose Monitoring | Abbott Laboratories | $4,819 | 0 |
| Prolongation of GLP-1 Adherence when using Continuous Glucose monitoring | Abbott Laboratories | $4,106 | 0 |
| FreeStyle Libre 2 Flash Glucose Monitoring System Intervention Phase Study | Abbott Laboratories | $4,000 | 0 |
| Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes (T1-DISCO) | Abbott Laboratories | $3,837 | 0 |
| Exploring Glycemia Profiles of Youth with Prediabetes through Continuous Glucose Monitoring | Abbott Laboratories | $2,766 | 0 |
| Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes (Ti-DISCO) | Abbott Laboratories | $2,066 | 0 |
| Dexcom G7 vs. FreeStyle Libre 3 Continuous Glucose Monitoring System Accuracy Study | Abbott Laboratories | $1,000 | 0 |
Top Doctors Receiving Payments for FreeStyle Libre 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Santa Barbara, CA | $962,143 | 105 |
| , MD | Internal Medicine | Cleveland, OH | $75,000 | 1 |
Ad
Manufacturing Companies
- Abbott Laboratories $1.0M
Product Information
- Type Device
- Total Payments $1.0M
- Total Doctors 1
- Transactions 106
About FreeStyle Libre 3
FreeStyle Libre 3 is a device associated with $1.0M in payments to 1 healthcare providers, recorded across 106 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.
Payment data is available from 2021 to 2024. In 2024, $314,046 was paid across 55 transactions to 1 doctors.
The most common payment nature for FreeStyle Libre 3 is "Unspecified" ($1.0M, 100.0% of total).
FreeStyle Libre 3 is associated with 19 research studies, including "Dexcom G7 vs FreeStyle Libre 3 Continuous Glucose Monitoring System Accuracy Study" ($495,148).